Trial reportBritish journal of clinical pharmacology2021
Liver and kidney function in patients with Covid-19 treated with remdesivir.
Trial report in British journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Liver and kidney function in patients with Covid-19 treated with remdesivir.British journal of clinical pharmacology · 2021Trial
- Remdesivir in COVID-19: pros and cons.Frontiers in pharmacology · 2026Review
- COVID-19 Infection, Drugs, and Liver Injury.Journal of clinical medicine · 2025Review
- Unlocking the potential of remdesivir: innovative approaches to drug delivery.Drug delivery and translational research · 2025Review
- Comparative Analysis of Neuropsychiatric Adverse Reactions Associated with Remdesivir and Nirmatrelvir/Ritonavir in COVID-19 Treatment: Insights from EudraVigilance Data.Journal of clinical medicine · 2025Article
- Adverse drug reactions associated with COVID-19 management.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- An in vitro study for reducing the cytotoxicity and dose dumping risk of remdesivir via entrapment in nanostructured lipid carriers.Scientific reports · 2024Article
- SARS-CoV-2 Infection Is an Independent Risk Factor for Decompensation in Cirrhosis Patients.Diseases (Basel, Switzerland) · 2024Article
- COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?International journal of molecular sciences · 2024Review
- The effect of remdesivir on mortality and the outcome of patients with COVID-19 in intensive care unit: A case-control study.Health science reports · 2023Article
- COVID-19 and Fatty Liver Disorders.Journal of clinical medicine · 2023Review
- COVID-19 and liver injury: Pathophysiology, risk factors, outcome and management in special populations.World journal of hepatology · 2023Review
- Evaluation of Remdesivir Utilization Pattern in Critically Ill Patients With COVID-19 in Jazan Province.Cureus · 2023Article
- Complicated appendicitis, acute pancreatitis, pleural effusion, and sinus bradycardia in a COVID-19 patient.Clinical case reports · 2023Article
- Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19.Frontiers in medicine · 2023Article
- Liver injury induced by COVID 19 treatment - what do we know?World journal of gastroenterology · 2022Review
- Care of the Seriously Ill Patient with SARS-CoV-2.The Medical clinics of North America · 2022Review
- Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: a self-controlled case series study.Alimentary pharmacology & therapeutics · 2022Article
- Adverse events following remdesivir administration in moderately ill COVID-19 patients - A retrospective analysis.Journal of family medicine and primary care · 2022Article
- Kidney implications of SARS-CoV2 infection in children.Pediatric nephrology (Berlin, Germany) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For the treatment of Covid-19 patients with remdesivir, poor renal and liver function were both exclusion criteria in randomized clinical trials and contraindication for treatment. Also, nephrotoxicity and hepatotoxicity are reported as adverse events. We retrospectively reviewed renal and liver functions of Covid-19 103 patients who received remdesivir in the 15 days after treatment initiation. Approximately 20% of the patient population met randomized clinical trial exclusion criteria. In total, 11% of the patients had a decrease in estimated glomerular filtration rate >10 mL/min/1.73m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.